15M

(5Z)-7-{(1R,2R,3R,5S)-3,5-DIHYDROXY-2-[(1E,3S)-3-HYDROXY-5-PHENYLPENT-1-ENYL]CYCLOPENTYL}-N-ETHYLHEPT-5-ENAMIDE

Find entries where: 15M

is present as a standalone ligand in 1 entries

Find related ligands:

Chemical Component Summary
Name	(5Z)-7-{(1R,2R,3R,5S)-3,5-DIHYDROXY-2-[(1E,3S)-3-HYDROXY-5-PHENYLPENT-1-ENYL]CYCLOPENTYL}-N-ETHYLHEPT-5-ENAMIDE
Synonyms	BIMATOPROST
Identifiers	(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenyl-pent-1-enyl]cyclopentyl]-N-ethyl-hept-5-enamide
Formula	C₂₅ H₃₇ N O₄
Molecular Weight	415.566
Type	NON-POLYMER
Isomeric SMILES	CCNC(=O)CCC\C=C/C[C@H]1[C@H](C[C@H]([C@@H]1\C=C\[C@H](CCc2ccccc2)O)O)O
InChI	InChI=1S/C25H37NO4/c1-2-26-25(30)13-9-4-3-8-12-21-22(24(29)18-23(21)28)17-16-20(27)15-14-19-10-6-5-7-11-19/h3,5-8,10-11,16-17,20-24,27-29H,2,4,9,12-15,18H2,1H3,(H,26,30)/b8-3-,17-16+/t20-,21+,22+,23-,24+/m0/s1
InChIKey	AQOKCDNYWBIDND-FTOWTWDKSA-N

Chemical Details
Formal Charge	0
Atom Count	67
Chiral Atom Count	5
Bond Count	68
Aromatic Bond Count	6

Drug Info: DrugBank

DrugBank ID	DB00905
Name	Bimatoprost
Groups	approved investigational
Description	Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and glaucoma.[L6877,L6892,L6898,L12069] Bimatoprost is also used to treat eyelash hypotrichosis, or sparse eyelash growth.[L6910] It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug.[L4894]
Synonyms	Bimatoprostum (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide Bimatoprost
Brand Names	Lumigan Lumigan PF Durysta Lumigan Rc Ganfort Vistitan Apo-bimatoprost Latisse Bimatoprost Zimed PF
Indication	Bimatoprost is used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. These patients must be intolerant to other intraocular pressure lowering medications or inadequately responsive to other treatments.[L6877] Bimatoprost is also indicated to treat eyelash hypotrichosis.[L6910]
Categories	Amides Antiglaucoma Preparations and Miotics Antihypertensive Agents Autacoids Biological Factors Cardiovascular Agents Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 CYP3A5 Substrates Cytochrome P-450 Substrates Drugs that are Mainly Renally Excreted Eicosanoids Fatty Acids Fatty Acids, Unsaturated Inflammation Mediators Lipids Ophthalmologicals Prostaglandin analogs reducing intraocular pressure (IOP) Prostaglandins Prostaglandins F, Synthetic Prostaglandins, Synthetic Sensory Organs
ATC-Code	S01EE03
CAS number	155206-00-1

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
Prostaglandin F2-alpha receptor	MSMNNSKQLVSPAAALLSNTTCQTENRLSVFFSVIFMTVGILSNSLAIAI...	unknown	agonist
Prostaglandin E2 receptor EP1 subtype	MSPCGPLNLSLAGEATTCAAPWVPNTSAVPPSGASPALPIFSMTLGAVSN...	unknown	agonist
Prostaglandin E2 receptor EP3 subtype	MKETRGYGGDAPFCTRLNHSYTGMWAPERSAEARGNLTRPPGSGEDCGSV...	unknown	agonist
Cytochrome P450 3A4	MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...	unknown	substrate
Cytochrome P450 3A5	MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNV...	unknown	substrate

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682